Kakao Healthcare and CNR Research Sign Business Agreement to Jointly Promote Clinical Projects

Kakao Healthcare announced on the 19th that it has signed a business agreement with C&R Research, Korea's first Clinical Research Organization (CRO), to jointly promote global clinical trial projects.

Kakao Healthcare announced on the 19th that it has signed a business agreement with C&R Research, the first domestic Contract Research Organization (CRO), to jointly promote global clinical trial projects. Hwang Hee, CEO of Kakao Healthcare (right), and Yoon Moon-tae, CEO of C&R Research, are posing for a commemorative photo.
[Photo by Kakao Healthcare]

The two companies will combine Kakao Healthcare's medical big data platform and artificial intelligence (AI) technology with C&R Research's expertise in clinical trials based on real-world data (RWD) and real-world evidence (RWE) to comprehensively collaborate on discovering global demand institutions, planning, and conducting clinical trials. In particular, they will promote clinical trials utilizing actual clinical data such as RWD and RWE together with historical trial data (HTD) from external control groups.

According to Kakao Healthcare, data-driven clinical trials and new drug development using RWD and RWE have recently accelerated both domestically and internationally. Government agencies and others are working on regulatory improvements to support this policy-wise.

In July, the two companies were selected as the final project operators for the "Smart Clinical Trial New Technology Development Research Project," which was announced by the Smart Clinical Trial New Technology Development Research Consortium, including Kyung Hee Medical Center. Through participation in the research project and joint business promotion, they plan to contribute to Korea's leap into the leading group in the data-driven clinical trial field.

Hwang Hee, CEO of Kakao Healthcare, said, "We expect to be able to design reliable external control group clinical trials through collaboration with C&R Research," adding, "Based on Kakao Healthcare's medical big data platform technology, RWE and RWD-based clinical research can be conducted more precisely and rapidly."

Yoon Moon-tae, CEO of C&R Research, said, "We will continue to cooperate with Kakao Healthcare to establish methodologies for building external control groups that can be recognized for validity both domestically and internationally," and added, "Aiming at the global market, we will secure expertise in all aspects of external control group clinical trials so that C&R Research can become a hub for domestic pharmaceutical and bio companies' global expansion."

This content was produced with the assistance of AI translation services.